The frequent need for three or more drugs to treat essential hypertension. What evidence for optimal combinations?

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 3, Issue 2, 2002, Pages 103-108

  Swift, Pauline A ^a   MacGregor, Graham A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Drug combinations; Hypertension; Third line agents; Treatment targets

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LABETALOL; LISINOPRIL; METHYLDOPA; MINOXIDIL; NIFEDIPINE; PLACEBO; PRAZOSIN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VASODILATOR AGENT; VERAPAMIL;

ADULT; AGED; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG POTENTIATION; DRUG USE; ESSENTIAL HYPERTENSION; HUMAN; ISCHEMIC HEART DISEASE; MORBIDITY; OUTCOMES RESEARCH; REVIEW; RISK FACTOR; STROKE; UNITED KINGDOM; DRUG COMBINATION; HYPERTENSION;

ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; HUMAN; HYPERTENSION; HUMANS;

EID: 0036615525     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2002.010     Document Type: Review

References (40)

1. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg
2. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed clinical trials
3. Cardiovascular protection and blood pressure reduction
4. British Hypertension Society guidelines for hypertension management 1999: Summary
5. 1999 World Health Organisation-International Society of Hypertension Guidelines for the Management of Hypertension
6. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
7. Improved hypertension management and control. Results from the Health Survey for England 1998
8. Hypertension awareness, treatment and control in the community: Is the 'rule of halves' still valid?
9. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principle results of the Hypertension Optimal Treatment (HOT) randomised trial
10. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity: The Swedish Trial in Old Patients with Hypertension-2 study
11. Randomised double-blind comparison of placebo and active treatment for older patients with isolated hypertension
12. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
13. Preserving renal function in adults with hypertension and diabetes: A consensus approach
14. Optimisation of antihypertensive treatment by crossover rotation of four major classes
15. Single-Drug Therapy for Hypertension in Men - A Comparison of Six Antihypertensive Agents with Placebo
16. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study
17. Comparison of different fixed antihypertensive combination drugs: A double-blind, placebo-controlled parallel group study
18. A double-blind study of the concomitant diuretic therapy in hypertensive patients treated with amlodipine
19. Chlorthalidone does not increase the hypotensive effect of nifedipine in essential hypertensives in a crossover multicentre study
20. Captopril in essential hypertension: Contrasting effects of adding hydrochlorothiazide or propranolol
21. Treatment of hypertension with enalapril and hydrochlorothiazide or enalapril and atenolol: Contrasts in hypotensive interactions
22. Influence of the angiotensin converting enzyme inhibitor cilazapril, the beta blocker propranolol and their combination on haemodynamics in hypertension
23. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial
24. The St. George's 'Star' and 'Imploding Diamond'
25. Mortality in patients of the Glasgow Blood Pressure Clinic
26. 'Third drug' trial: Comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic
27. Evaluation of the efficacy and safety of enalapril plus hydrochlorothiazide plus methyldopa vs. standard triple therapy in the treatment of moderate to severe hypertension: Results from a multicentre study
28. Comparison of captopril, hydralazine and nifedipine as third drug in hypertensive patients
29. Effects of atenolol withdrawal in patients on triple antihypertensive therapy
30. A diuretic is more effective than a β-blocker in hypertensive patients not controlled on amlodipine and lisinopril
31. The treatment of severe hypertension with trandolapril, verapamil and hydrochlorothiazide
32. Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension
33. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) Diet
34. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
35. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
36. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
37. Renal protective effect of enalapril in diabetic nephropathy
38. Renoprotective effects of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
39. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy